Des C. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Des C. Jones has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Rachel Louise Allen
University of Suffolk, Ipswich, UK
3 shared publications Chiwen Chang
Immunology Division, Department of Pathology, University of Cambridge , Cambridge CB2 1QP
2 shared publicationsJohn Trowsdale
Immunology Division, Department of Pathology, University of Cambridge , Cambridge CB2 1QP
2 shared publications- Nicolas Lapaque
Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, France
2 shared publications Ali Roghanian
Division of Immunology, Department of Pathology, University of Cambridge, UK
1 shared publicationAzumi Kono
Department of Basic Medical Science and Molecular Medicine, Tokai University School of Medicine , Isehara, Kanagawa 259-1143
1 shared publication
Latest Publications
- Open Access
- 1 March 2011
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 186 (5) , 2990-2997
HLA Class I Allelic Sequence and Conformation Regulate Leukocyte Ig-Like Receptor Binding
Leukocyte Ig-like receptors (LILRs) are a family of innate immune receptors predominantly expressed by myeloid cells that can alter the Ag presentation properties of macrophages and dendritic cells. Several LILRs bind HLA class I. Altered LILR recognition due to HLA allelic variation could be a contributing factor in disease. We comprehensively assessed LILR binding to >90 HLA class I alleles. The inhibitory receptors LILRB1 and LILRB2 varied in their level of binding to different HLA alleles, correlating in some cases with specific amino acid motifs. LILRB2 displayed the weakest binding to HLA-B*2705, an allele genetically associated with several autoimmune conditions and delayed progression of HIV infection. We also assessed the effect of HLA class I conformation on LILR binding. LILRB1 exclusively bound folded β2-microglobulin–associated class I, whereas LILRB2 bound both folded and free H chain forms. In contrast, the activating receptor LILRA1 and the soluble LILRA3 protein displayed a preference for binding to HLA-C free H chain. To our knowledge, this is the first study to identify the ligand of LILRA3. These findings support the hypothesis that LILR-mediated detection of unfolded versus folded MHC modulates immune responses during infection or inflammation.
- 1 March 2011
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 186 (5) , 2990-2997
Open AccessHLA Class I Allelic Sequence and Conformation Regulate Leukocyte Ig-Like Receptor Binding
Leukocyte Ig-like receptors (LILRs) are a family of innate immune receptors predominantly expressed by myeloid cells that can alter the Ag presentation properties of macrophages and dendritic cells. Several LILRs bind HLA class I. Altered LILR recognition due to HLA allelic variation could be a contributing factor in disease. We comprehensively assessed LILR binding to >90 HLA class I alleles. The inhibitory receptors LILRB1 and LILRB2 varied in their level of binding to different HLA alleles, correlating in some cases with specific amino acid motifs. LILRB2 displayed the weakest binding to HLA-B*2705, an allele genetically associated with several autoimmune conditions and delayed progression of HIV infection. We also assessed the effect of HLA class I conformation on LILR binding. LILRB1 exclusively bound folded β2-microglobulin–associated class I, whereas LILRB2 bound both folded and free H chain forms. In contrast, the activating receptor LILRA1 and the soluble LILRA3 protein displayed a preference for binding to HLA-C free H chain. To our knowledge, this is the first study to identify the ligand of LILRA3. These findings support the hypothesis that LILR-mediated detection of unfolded versus folded MHC modulates immune responses during infection or inflammation.
- Open Access
- 30 October 2009
- Published by Wiley in European Journal of Immunology
- Vol. 39 (11) , 3195-3206
Alternative mRNA splicing creates transcripts encoding soluble proteins from most LILR genes
Leucocyte Ig‐like receptors (LILR) are a family of innate immune receptors expressed on myeloid and lymphoid cells that influence adaptive immune responses. We identified a common mechanism of alternative mRNA splicing, which generates transcripts that encode soluble protein isoforms of the majority of human LILR. These alternative splice variants lack transmembrane and cytoplasmic encoding regions, due to the transcription of a cryptic stop codon present in an intron 5′ of the transmembrane encoding exon. The alternative LILR transcripts were detected in cell types that express their membrane‐associated isoforms. Expression of the alternative LILRB1 transcript in transfected cells resulted in the release of a soluble ∼65 Kd LILRB1 protein into culture supernatants. Soluble LILRB1 protein was also detected in the culture supernatants of monocyte‐derived DC. In vitro assays suggested that soluble LILRB1 could block the interaction between membrane‐associated LILRB1 and HLA‐class I. Soluble LILRB1 may act as a dominant negative regulator of HLA‐class I‐mediated LILRB1 inhibition. Soluble isoforms of the other LILR may function in a comparable way.
- 30 October 2009
- Published by Wiley in European Journal of Immunology
- Vol. 39 (11) , 3195-3206
Open AccessAlternative mRNA splicing creates transcripts encoding soluble proteins from most LILR genes
Leucocyte Ig‐like receptors (LILR) are a family of innate immune receptors expressed on myeloid and lymphoid cells that influence adaptive immune responses. We identified a common mechanism of alternative mRNA splicing, which generates transcripts that encode soluble protein isoforms of the majority of human LILR. These alternative splice variants lack transmembrane and cytoplasmic encoding regions, due to the transcription of a cryptic stop codon present in an intron 5′ of the transmembrane encoding exon. The alternative LILR transcripts were detected in cell types that express their membrane‐associated isoforms. Expression of the alternative LILRB1 transcript in transfected cells resulted in the release of a soluble ∼65 Kd LILRB1 protein into culture supernatants. Soluble LILRB1 protein was also detected in the culture supernatants of monocyte‐derived DC. In vitro assays suggested that soluble LILRB1 could block the interaction between membrane‐associated LILRB1 and HLA‐class I. Soluble LILRB1 may act as a dominant negative regulator of HLA‐class I‐mediated LILRB1 inhibition. Soluble isoforms of the other LILR may function in a comparable way.
- Open Access
- 27 October 2009
- Published by Springer Nature in BMC Immunology
- Vol. 10 (1) , 56
The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection
Background: Leukocyte Ig-like receptors (LILR) are a family of innate immune receptors with immunomodulatory functions. High-level expression of the receptors LILRB2 (ILT4) and LILRB4 (ILT3) is a feature of tolerogenic antigen presenting cells and has been observed in cancer and transplant situations. There are relatively few studies regarding these receptors in the context of infection and it is not yet clear how LILRB4 exerts its inhibitory effects. Results: We studied the effects of LILRB4 ligation on antigen presenting cell phenotype, and the expression of LILRB2 and LILRB4 on Salmonella- infected antigen presenting cells. Ligation of LILRB4 throughout in vitro culture of dendritic cells led to an upregulation of the co-stimulatory protein CD86. Alterations in the production of IL-8 and IL-10 by LILRB4-ligated macrophages were also observed. Infection with Salmonella typhimurium or TLR stimulation with Salmonella components led to an upregulation of LILRB2 and LILRB4. Conclusion: Our results indicate that the inhibitory effects of LILRB4 do not result from a failure to upregulate co-stimulatory proteins. In addition to the high level expression that can render antigen presenting cells tolerogenic, there may be a role for lower level expression and activity of LILRB2 and LILRB4 in response to TLR signalling during an immune response to bacterial infection.
- 27 October 2009
- Published by Springer Nature in BMC Immunology
- Vol. 10 (1) , 56
Open AccessThe inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection
Background: Leukocyte Ig-like receptors (LILR) are a family of innate immune receptors with immunomodulatory functions. High-level expression of the receptors LILRB2 (ILT4) and LILRB4 (ILT3) is a feature of tolerogenic antigen presenting cells and has been observed in cancer and transplant situations. There are relatively few studies regarding these receptors in the context of infection and it is not yet clear how LILRB4 exerts its inhibitory effects. Results: We studied the effects of LILRB4 ligation on antigen presenting cell phenotype, and the expression of LILRB2 and LILRB4 on Salmonella- infected antigen presenting cells. Ligation of LILRB4 throughout in vitro culture of dendritic cells led to an upregulation of the co-stimulatory protein CD86. Alterations in the production of IL-8 and IL-10 by LILRB4-ligated macrophages were also observed. Infection with Salmonella typhimurium or TLR stimulation with Salmonella components led to an upregulation of LILRB2 and LILRB4. Conclusion: Our results indicate that the inhibitory effects of LILRB4 do not result from a failure to upregulate co-stimulatory proteins. In addition to the high level expression that can render antigen presenting cells tolerogenic, there may be a role for lower level expression and activity of LILRB2 and LILRB4 in response to TLR signalling during an immune response to bacterial infection.
- 11 December 2003
- Published by Wiley in European Journal of Immunogenetics
- Vol. 30 (6) , 415-419
Human platelet alloantigens (HPAs): PCR‐SSP genotyping of a UK population for 15 HPA alleles
Summary: Alloimmunization to human platelet alloantigens (HPAs) is responsible for neonatal alloimmune thrombocytopenia (NAIT), post‐transfusional purpura (PTP) and platelet transfusion refractoriness. HPAs may also have a role as histocompatibility antigens in transplantation as well as associations with cardiac disease. We have developed a polymerase chain reaction–sequence‐specific primer (PCR‐SSP) assay capable of detecting 15 HPA allelic variants. As part of the validation of the assay, 134 UK renal donors were genotyped to determine HPA allele frequencies in the UK population. The HPA allele frequencies obtained are consistent with those of the other European studies: GP1A*1 (HPA‐5a) and GP1A*2 (HPA‐5b), 0.914 and 0.086, respectively; GP1BA*1 (HPA‐2a) and GP1BA*2 (HPA‐2b), 0.925 and 0.075; GP2B*1 (HPA‐3a) and GP2B*2 (HPA‐3b), 0.627 and 0.373; GP3A*1 (HPA‐1a) and GP3A*2 (HPA‐1b), 0.840 and 0.161. The rare alleles GP2B*3 (HPA‐9bw) and GP3A*3 to *8 (HPA‐4b, ‐6b, ‐7bw, ‐8bw, ‐10bw and ‐11bw, respectively) were all absent. This comprehensive HPA genotyping assay allows rapid, accurate and reproducible results at low cost.
- 11 December 2003
- Published by Wiley in European Journal of Immunogenetics
- Vol. 30 (6) , 415-419
Human platelet alloantigens (HPAs): PCR‐SSP genotyping of a UK population for 15 HPA alleles
Summary: Alloimmunization to human platelet alloantigens (HPAs) is responsible for neonatal alloimmune thrombocytopenia (NAIT), post‐transfusional purpura (PTP) and platelet transfusion refractoriness. HPAs may also have a role as histocompatibility antigens in transplantation as well as associations with cardiac disease. We have developed a polymerase chain reaction–sequence‐specific primer (PCR‐SSP) assay capable of detecting 15 HPA allelic variants. As part of the validation of the assay, 134 UK renal donors were genotyped to determine HPA allele frequencies in the UK population. The HPA allele frequencies obtained are consistent with those of the other European studies: GP1A*1 (HPA‐5a) and GP1A*2 (HPA‐5b), 0.914 and 0.086, respectively; GP1BA*1 (HPA‐2a) and GP1BA*2 (HPA‐2b), 0.925 and 0.075; GP2B*1 (HPA‐3a) and GP2B*2 (HPA‐3b), 0.627 and 0.373; GP3A*1 (HPA‐1a) and GP3A*2 (HPA‐1b), 0.840 and 0.161. The rare alleles GP2B*3 (HPA‐9bw) and GP3A*3 to *8 (HPA‐4b, ‐6b, ‐7bw, ‐8bw, ‐10bw and ‐11bw, respectively) were all absent. This comprehensive HPA genotyping assay allows rapid, accurate and reproducible results at low cost.